Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from Biktarvy to Dovato in virologically suppressed adults ≥50 years with HIV
2022-503137-66-00Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, open-label, single-arm trial of dolutegravir + lamivudine in human immunodeficiency virus infection (HIV), sponsored by ViiV Healthcare. Primary endpoint: Participants with plasma HIV-1 RNA ≥50 copies/mL at Week 48 (FDA Snapshot algorithm). Started Nov 2023; status: completed.
02
Drugs
dolutegravir + lamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2022-503137-66-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503137-66-00.